Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Pyridines/administration & dosage"'
Autor:
Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, Karen McCoy, Scott Donaldson, Seth Walker, James Chmiel, Ronald Rubenstein, Deborah K. Froh, Isabel Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor-Cousar, Bruce Barnett, Gary Mueller, Patrick Flume, Floyd Livingston, Nighat Mehdi, Charlotte Teneback, John Welter, Raksha Jain, Dana Kissner, Kapilkumar Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross Carl Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, Damien Downey, Gary Connett, Edward Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, Francois Vermeulen, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof Majoor
Publikováno v:
Lancet, 394(10212), 1940-1948. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221e25362cf07bd88d1d3728962d9a50
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK
Autor:
Sophie Clément, Pierre O. Chappuis, Alexandre Bodmer, Krisztian Homicsko, Yann Christinat, Melinda Charrier, Olivier Michielin, Petros Tsantoulis, Daniele Frisone, Thomas Alexander Mckee, Laure Thouvenin
Publikováno v:
Cancer biology & therapy, vol. 21, no. 3, pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352c882e2c41b9625dab34c1f829ff27
https://doi.org/10.1080/15384047.2019.1685291
https://doi.org/10.1080/15384047.2019.1685291
Autor:
Kang Yell Choi, Jong Chan Park, Jeong Su Yoon, Yong Hee Cho, Dong Woo Kang, Eun Ji Ro, Hans Clevers, Tae Il Kim, Tomohiro Mizutani
Publikováno v:
Nature Communications, 11(1). Nature Publishing Group
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Nature Communications
5-Fluorouracil (5-FU) remains the first-line treatment for colorectal cancer (CRC). Although 5-FU initially de-bulks the tumor mass, recurrence after chemotherapy is the barrier to effective clinical outcomes for CRC patients. Here, we demonstrate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5c3cd05c8716e3e7fd22f0717726d0f
https://hdl.handle.net/20.500.11755/de483e27-9a68-49de-bf37-80bb92ac9c00
https://hdl.handle.net/20.500.11755/de483e27-9a68-49de-bf37-80bb92ac9c00
Autor:
André Scherag, Magali Reiser, T Doenst, Christina Forstner, Stefan Hagel, Frank M. Brunkhorst, Mathias W. Pletz, Stéphan Juergen Harbarth
Publikováno v:
Journal of Hospital Infection, Vol. 95, No 2 (2017) pp. 137-143
Summary Objective To evaluate the effect of pre-operative octenidine (OCT) decolonization on surgical site infection (SSI) rates. Design Before-and-after cohort study. Patients Patients undergoing an elective isolated coronary artery bypass graft (CA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00bbdd0986a12591374127158e423a0d
https://doi.org/10.1016/j.jhin.2016.11.004
https://doi.org/10.1016/j.jhin.2016.11.004
Autor:
VX17-445-103 Trial Group
Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10691::89138b60eee52c990cd8474204258594
https://dspace.library.uu.nl/handle/1874/391989
https://dspace.library.uu.nl/handle/1874/391989
Autor:
Gregory Y.H. Lip
Publikováno v:
Lip, G Y H 2019, ' The safety of NOACs in atrial fibrillation patient subgroups : A narrative review ', International Journal of Clinical Practice, vol. 73, no. 2, e13285 . https://doi.org/10.1111/ijcp.13285
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
AIM: Four non-vitamin K oral anticoagulants (NOACs) have been evaluated in clinical trials for the prevention of stroke in patients with atrial fibrillation (AF). Although each of the NOACs have been shown to be at least non-inferior to warfarin for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31a03596faff0bfee86879256cde1c4
https://vbn.aau.dk/ws/files/293589076/The_safety_of_NOACs_in_atrial_fibrillation_patient_subgroups_A_narrative_review.pdf
https://vbn.aau.dk/ws/files/293589076/The_safety_of_NOACs_in_atrial_fibrillation_patient_subgroups_A_narrative_review.pdf
Publikováno v:
Expert Opinion on Drug Delivery, Vol. 16, No 6 (2019) pp. 667-674
Background: The aim was to investigate cutaneous delivery and biodistribution of the hedgehog pathway inhibitor, vismodegib (VSD), indicated for basal cell carcinoma (BCC), from polymeric micelle formulations under infinite/finite dose conditions. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5db3465c9878795c129bc9617e45919e
Publikováno v:
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2− breast cancer with new targeted agents in combination with endocrine therapy : a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Introduction: Recently, new targeted agents have been developed, which can prolong the effect of endocrine treatment (ET) by targeting resistance pathways in HR+/HER2− advanced breast cancer. This review examines available studies of everolimus, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa0942932052480a705d1f354fa46e9
https://pubmed.ncbi.nlm.nih.gov/30375908
https://pubmed.ncbi.nlm.nih.gov/30375908
Autor:
Soumaya Marzouki, Melika Ben Ahmed, Jihene Bettaieb, Ines Bini Dhouib, Saloua El Fazaa, Chaouki Benabdessalem, Ammar Maroueni, Mohamed-Ridha Barbouche, Zakaria Bellasfar, Raoudha Doghri, Raja Rekik
Publikováno v:
Life Sciences
Life Sciences, Elsevier, 2018, 188, pp.10-16. ⟨10.1016/j.lfs.2017.08.022⟩
Life Sciences, Elsevier, 2018, 188, pp.10-16. ⟨10.1016/j.lfs.2017.08.022⟩
Aims Acetamiprid (ACE) is an insecticide of the neonicotinoid family, the most widely used in the world. Herein, we assessed the effect of ACE on either the humoral or cellular immune responses of rodents. We also evaluated the role of curcumin in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cea064f0778b4ffb9975a1fceb9d769
https://pubmed.ncbi.nlm.nih.gov/28843496
https://pubmed.ncbi.nlm.nih.gov/28843496
Autor:
Dominique de Valeriola, E. Brendel, Martine Piccart, Thierry Gil, M Mano, C. G. Haase, Brian Schwartz, S. Bartholomeus, Dirk Strumberg, Ahmad Awada, Alain Hendlisz
Publikováno v:
British Journal of Cancer, 92 (10
British Journal of Cancer
British Journal of Cancer
BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor (VEGFR) inhibitor that targets tumour cell proliferation and tumour angiogenesis. This Phase I study was undertaken to determine the safety profile, maximum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbdf7ffc381de061c888c7a31dedc122
https://doi.org/10.1038/sj.bjc.6602584
https://doi.org/10.1038/sj.bjc.6602584